Safety profile of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis: long-term interim results from the ENDORSE extension study

被引：0
|
作者：
Phillips, J. T. [1 ]
Fox, R. J. [2 ]
Selmaj, K. [3 ]
Yang, M. [4 ]
Zhang, R. [4 ]
Novas, M. [4 ]
Sweetser, M. T. [4 ]
Viglietta, V. [4 ]
Gold, R. [5 ]
机构：
[1] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA
[2] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[3] Med Univ Lodz, Lodz, Poland
[4] Biogen Idec Inc, Weston, MA USA
[5] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：457 / 457
页数：1
相关论文
共 50 条
  • [41] An integrated analysis of the clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from the phase 3 DEFINE and CONFIRM studies
    Fox, R. J.
    Miller, D. H.
    Phillips, J. T.
    Arnold, D. L.
    Selmaj, K.
    Yang, M.
    Zhang, R.
    Dawson, K. T.
    Viglietta, V.
    Sheikh, S. I.
    Gold, R.
    JOURNAL OF NEUROLOGY, 2013, 260 : S74 - S74
  • [42] Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM)
    Hutchinson, M.
    Bar-Or, A.
    Fox, R. J.
    Gold, R.
    Giovannoni, G.
    Kita, M.
    O'Gorman, J.
    Yang, M.
    Sheikh, S. I.
    Viglietta, V.
    Dawson, K. T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 682 - 683
  • [43] Sustained low rate of brain volume loss with long-term delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis patients: results from the ENDORSE study
    Miller, D.
    Yousry, T.
    Fox, R. J.
    Gold, R.
    Arnold, D. L.
    Potts, J.
    Marantz, J. L.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 550 - 551
  • [44] Clinical Efficacy of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
    Fox, Robert
    Miller, David
    Phillips, J. Theodore
    Arnold, Douglas
    Selmaj, Krzysztof
    Yang, Minhua
    Zhang, Ray
    Dawson, Katherine
    Viglietta, Vissia
    Sheikh, Sarah
    Gold, Ralf
    NEUROLOGY, 2013, 80
  • [45] Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study
    Bar-Or, Amit
    Gold, Ralf
    Kappos, Ludwig
    Arnold, Douglas
    Giovannoni, Gavin
    Selmaj, Krzysztof
    O'Gorman, John
    Stephan, Monica
    Dawson, Katherine
    NEUROLOGY, 2012, 78
  • [46] THE BUDGET IMPACT OF INTRODUCING BG-12 (DIMETHYL FUMARATE) FOR TREATMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS (RRMS) IN CANADA
    Dorman, E.
    Kansal, A. R.
    Sarda, S.
    VALUE IN HEALTH, 2013, 16 (07) : A620 - A620
  • [47] Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated clinical efficacy data from the DEFINE, CONFIRM, and ENDORSE studies
    Gold, R.
    Phillips, J. T.
    Bar-Or, A.
    Hutchinson, M.
    Kappos, L.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 222 - 222
  • [48] Efficacy of Oral BG-12 (Dimethyl Fumarate) in Patients Newly Diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Analysis of DEFINE and CONFIRM
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Fox, R. J.
    Rana, J.
    Zhang, A.
    Meltzer, L.
    Kurukulasuriya, N. C.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 931 - 932
  • [49] Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies
    Bar-Or, Amit
    Fox, Robert
    Gold, Ralf
    Miller, David
    Arnold, Douglas
    O'Gorman, John
    Yang, Minhua
    Sheikh, Sarah
    Viglietta, Vissia
    Dawson, Katherine
    Hutchinson, Michael
    NEUROLOGY, 2013, 80
  • [50] Effect of BG-12 (dimethyl fumarate) on freedom from measured clinical and neuroradiological disease activity over time in patients with relapsing remitting multiple sclerosis: results from the phase 3 studies
    Havrdova, E.
    Gold, R.
    Fox, R. J.
    Kappos, L.
    Phillips, J. T.
    Zhang, A.
    Kurukulasuriya, N. C.
    Sheikh, S. I.
    Viglietta, V.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 211 - 212
12345